You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 

CORPORATE

Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 

CORPORATE

Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. CORPORATE - 16-04-2014

    Kedrion Group approves 2013 financial statements

    Achieved results of 425 million euros turnover and a 25% profitability

    read more 
  2. PLASMA & BIOTHERAPIES - 14-04-2014

    Kedrion collection centers first to be certified in Hungary

    Plazmaferezis Állomás Kft achieves international PPTA certification

    read more 
  3. EVENTS - 01-04-2014

    Kedrion supports World Hemophilia Day

    The goal is to improve access to treatments for people suffering from hemophilia and other hemorrhagic conditions

    read more 
  4. EVENTS - 31-03-2014

    Award in the US for efforts to support hemophilia patients communities

    Kedrion’s Vice-President of North American Commercial Operations is “Man of the Year” for the Hemophilia Association of New Jersey

    read more 

Pages

For more information please contact: pressoffice@kedrion.com